An aging population is currently highlighting the
considerable limitations of the medical industry. According to the Mayo Clinic,
treatments are increasingly unable to keep pace with the needs of patients,
with clinicians only having access to medications or devices that can manage
symptoms. However, advances in developmental and cell biology, immunology and
related fields have unlocked huge potential for the industry, and regenerative
medicine looks to be the game-changing solution.
Despite its promise, regenerative medicine faces significant
hurdles moving forward. In particular, immune rejection of transplanted cells
has severely limited the huge potential of stem cell therapy. International
Stem Cell Corporation (OTCQB: ISCO), through its powerful new stem cell
technology, could be on the cusp of overcoming these limitations, opening the
door for major advances in the medical market.
Parthenogenesis, ISCO’s proprietary stem cell development
process, has allowed the company to develop a new class of stem cells, known as
human parthenogenetic stem cells (hpSCs), which possess the most favorable
characteristics of the existing classes. Through this technique, ISCO is able
to create cells that are exactly matched or histocompatible with large segments
of the human population, limiting the risk of immune rejection during
treatment.
ISCO has made noteworthy strides towards the
commercialization of its cell therapy treatment this year, capturing the
attention of industry experts around the globe.
“In the first quarter of 2015 we completed all the necessary
preclinical studies of our Parkinson’s program and formally submitted our
application to begin the first clinical study of this novel approach to
treating this debilitating disease in humans,” stated Andrey Semechkin, Ph.D.,
Chief Executive Officer and Co-Chairman of ISCO.
Highlights from the company’s business activity thus far in
2015 include the completion of preclinical studies and submission of an
application to begin human trials in Australia, completion of manufacture of a
bank of 2.6 billion human cells for use in clinical trials and the approval of
a Japanese patent covering parthenogenetic methods of stem cell creation,
meaning ISCO now has patent protection in all three major world markets (US, EU
and Japan).
“We continue to expect to make significant progress during
the rest of 2015 towards our goal of providing a viable treatment option for
people with Parkinson’s disease,” continued Semechkin.
According to Florida Hospital, Parkinson’s disease affects
up to one million people in the United States, with doctors diagnosing as many
as 60,000 new cases each year. Upon completion of clinical trials, the
potential market for ISCO’s parthenogenetic cell creation is effectively
limitless. As the company continues towards marketization for the treatment of
Parkinson’s disease, look for substantial opportunities for growth within the
medical industry in the years to come.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment